123 related articles for article (PubMed ID: 32988888)
21. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
[TBL] [Abstract][Full Text] [Related]
22. Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy.
Valizadeh A; Ahmadzadeh A; Saki G; Khodadadi A; Teimoori A
Asian Pac J Cancer Prev; 2015; 16(18):8533-9. PubMed ID: 26745113
[TBL] [Abstract][Full Text] [Related]
23. Engineered human mesenchymal stem cells for neuroblastoma therapeutics.
Nieddu V; Piredda R; Bexell D; Barton J; Anderson J; Sebire N; Kolluri K; Janes SM; Karteris E; Sala A
Oncol Rep; 2019 Jul; 42(1):35-42. PubMed ID: 31115546
[TBL] [Abstract][Full Text] [Related]
24. Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells.
Portanova P; Notaro A; Pellerito O; Sabella S; Giuliano M; Calvaruso G
Int J Oncol; 2013 Jul; 43(1):121-30. PubMed ID: 23686163
[TBL] [Abstract][Full Text] [Related]
25. Embelin downregulated cFLIP in breast cancer cell lines facilitate anti-tumor effect of IL-1β-stimulated human umbilical cord mesenchymal stem cells.
Liang YH; Wu JM; Teng JW; Hung E; Wang HS
Sci Rep; 2021 Jul; 11(1):14720. PubMed ID: 34282169
[TBL] [Abstract][Full Text] [Related]
26. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.
Ruiz-Ruiz C; López-Rivas A
Biochem J; 2002 Aug; 365(Pt 3):825-32. PubMed ID: 11936954
[TBL] [Abstract][Full Text] [Related]
27. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Tang XJ; Lu JT; Tu HJ; Huang KM; Fu R; Cao G; Huang M; Cheng LH; Dai LJ; Zhang L
Anticancer Res; 2014 Feb; 34(2):729-34. PubMed ID: 24511006
[TBL] [Abstract][Full Text] [Related]
28. IFNγ and TNFα synergistically induce apoptosis of mesenchymal stem/stromal cells via the induction of nitric oxide.
Li X; Shang B; Li YN; Shi Y; Shao C
Stem Cell Res Ther; 2019 Jan; 10(1):18. PubMed ID: 30635041
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.
Loebinger MR; Eddaoudi A; Davies D; Janes SM
Cancer Res; 2009 May; 69(10):4134-42. PubMed ID: 19435900
[TBL] [Abstract][Full Text] [Related]
30. The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB
Cancer Biol Ther; 2012 Oct; 13(12):1175-84. PubMed ID: 22922789
[TBL] [Abstract][Full Text] [Related]
31. Caudatin potentiates the anti-tumor effects of TRAIL against human breast cancer by upregulating DR5.
Fei HR; Yuan C; Wang GL; Zhao Y; Li ZJ; Du X; Wang FZ
Phytomedicine; 2019 Sep; 62():152950. PubMed ID: 31102888
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
33. Intravenous Anesthetics Enhance the Ability of Human Bone Marrow-Derived Mesenchymal Stem Cells to Alleviate Hepatic Ischemia-Reperfusion Injury in a Receptor-Dependent Manner.
Feng J; Yao W; Zhang Y; Xiang AP; Yuan D; Hei Z
Cell Physiol Biochem; 2018; 47(2):556-566. PubMed ID: 29794450
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
[TBL] [Abstract][Full Text] [Related]
35. Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy.
Wang Z; Chen H; Wang P; Zhou M; Li G; Hu Z; Hu Q; Zhao J; Liu X; Wu L; Liang D
Stem Cells Transl Med; 2022 Mar; 11(3):297-309. PubMed ID: 35267023
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
[TBL] [Abstract][Full Text] [Related]
37. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect of conditioned media derived from murine MSCs and 5-aminolevulinic acid (5-ALA) mediated photodynamic therapy in breast cancer in vitro.
Mohammadpour H; Majidzadeh-A K
Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):238-43. PubMed ID: 25721458
[TBL] [Abstract][Full Text] [Related]
39. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
[TBL] [Abstract][Full Text] [Related]
40. Encapsulated human mesenchymal stem cells (eMSCs) as a novel anti-cancer agent targeting breast cancer stem cells: Development of 3D primed therapeutic MSCs.
Mandal S; Arfuso F; Sethi G; Dharmarajan A; Warrier S
Int J Biochem Cell Biol; 2019 May; 110():59-69. PubMed ID: 30735730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
